Core Viewpoint - Hualan Co., Ltd. is expanding its presence in the "AI + Medicine" sector through the establishment of a joint venture focused on drug repurposing and pharmacovigilance services, leveraging knowledge graphs and advanced technology partnerships [1][3][4] Group 1: Company Developments - Hualan Co., Ltd. has established a subsidiary, Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd. (Lingqing Intelligent), to explore AI applications in the pharmaceutical industry [1][6] - The company plans to collaborate with a technical team led by former CTO of Insilico LLC, Yu Kaixian, and Academician Liu Jun to set up a joint venture that will focus on intelligent solutions for drug development and safety management [3][4] - The joint venture will be controlled by Lingqing Intelligent and aims to integrate heterogeneous data sources to enhance drug research and safety management [3][5] Group 2: Investment Strategy - Hualan Co., Ltd. has made significant investments in AI pharmaceutical companies, including a recent capital increase of 450 million yuan to Lingqing Intelligent, raising its registered capital to 500 million yuan [6][7] - The company is also establishing an AI Pharmaceutical Expert Committee to provide strategic planning and technical guidance for its AI-related business [7] Group 3: Market Context and Challenges - The AI pharmaceutical sector is characterized by high technical barriers and requires substantial investment in computing power, funding, and talent, which may pose operational pressures for companies with insufficient technical accumulation [5][9] - Despite the potential for efficiency gains in drug repurposing and pharmacovigilance, the competitive landscape is challenging, with established players having a head start [5][10] Group 4: Board Concerns - Two board members, Cui Ke and Yao Mingfang, opposed the establishment of the joint venture, citing the need for thorough feasibility assessments and governance structures to ensure efficient use of funds and sustainable development [9][10] - Their concerns reflect a cautious approach to the company's foray into the AI pharmaceutical field, emphasizing the importance of evaluating key factors such as data sources and commercialization pathways [10]

Core Viewpoint - Hualan Co., Ltd. announced a collaboration between its wholly-owned subsidiary, Hainan Lingqing Smart Pharmaceutical Technology Co., Ltd., and a technical team led by former CTO of Insilico Liu Kaixian and Academician Liu Jun from the American Academy of Sciences to establish a joint venture focused on drug repurposing and pharmacovigilance services using knowledge graphs [1][2]. Group 1 - The joint venture will be controlled by Lingqing Smart and will be included in the company's consolidated financial statements [1]. - The venture aims to provide intelligent solutions for drug research and safety management by integrating heterogeneous data sources [1]. - The specific business scope will be defined according to the business registration information [1]. Group 2 - To enhance the long-term development motivation of the joint venture, the company plans to implement a performance-based partnership incentive arrangement linked to business targets [2]. - This incentive will involve transferring partnership shares through Holding Platform 1 to motivate key personnel and others who significantly contribute to the joint venture's development [2]. - The arrangement aims to align the interests of core personnel with the long-term success of the venture, promoting risk-sharing and long-term incentives [2].

华兰股份公告，全资子公司海南灵擎数智医药科技有限公司拟与美国Insilicom LLC前首席技术官俞开先 及美国科学院院士LIU JUN（刘军）领衔的技术团队共同出资设立合资公司，其中灵擎数智出资600万 元，持股60%。合资公司聚焦以知识图谱为核心的药物重定向与药物警戒相关服务，旨在探索 人工智 能技术在医药研发与药物安全管理领域的应用场景。 ...